Ganoderma lucidum Combined with the EGFR Tyrosine Kinase Inhibitor, Erlotinib Synergize to Reduce Inflammatory Breast Cancer Progression

The high incidence of resistance to Tyrosine Kinase Inhibitors (TKIs) targeted against EGFR and downstream pathways has increased the necessity to identify agents that may be combined with these therapies to provide a sustained response for breast cancer patients. Here, we investigate the therapeuti...

Descripción completa

Detalles Bibliográficos
Autores principales: Suárez-Arroyo, Ivette J., Rios-Fuller, Tiffany J., Feliz-Mosquea, Yismeilin R., Lacourt-Ventura, Mercedes, Leal-Alviarez, Daniel J., Maldonado-Martinez, Gerónimo, Cubano, Luis A., Martínez-Montemayor, Michelle M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4780125/
https://www.ncbi.nlm.nih.gov/pubmed/26958085
http://dx.doi.org/10.7150/jca.13599

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4780125/
https://www.ncbi.nlm.nih.gov/pubmed/26958085
http://dx.doi.org/10.7150/jca.13599

Ejemplares similares